JPRN-jRCT2080222529已完成1 期
Phase I Study of RO5541077 in Patients with B cell Non-Hodgkin s Lymphoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 7
研究概览
简要总结
This study demonstrated that RO5541077 were well tolerated and no DLTs were observed within the dose range of up to 1.8 mg/kg in Japanese patients with B-cell non-Hodgkin lymphoma.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •Performance status (PS) of 0 or 1
- •Relapsed or refractory B cell NHL for which there is no prior standard treatment
- •Sufficient major organ function
排除标准
- •Pregnant or lactating women or women who have tested positive on a pregnancy test
- •Current or previous history of clinically significant disease
- •Current or previous history of central nervous system lymphoma
- •Invasion to the CNS of the primary disease
研究者
相似试验
已完成
1 期
A PHASE I STUDY OF RO7082859 IN PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMAon Hodgkin's LymphomaJPRN-jRCT2080225077Chugai Pharmaceutical Co., Ltd.12
终止
1 期
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell MalignanciesRichter TransformationNCT05828589BeOne Medicines51
已完成
1 期
A Study of BBP-711 (ORF-229) in Healthy Adult VolunteersHealthyNCT04876924Cantero Therapeutics, a BridgeBio company92
招募中
1 期
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast CancerMetastatic Breast CancerHormone-receptor-positive Breast CancerHER2-negative Breast CancerNCT06756932BeOne Medicines120
已完成
1 期
Study of the Safety, Tolerability and Immunogenicity of an Intranasal Influenza Vaccine Administered to Healthy AdultsFlu, HumanNCT03293732Advagene Biopharma Co. Ltd.36